Soleno Therapeutics (SLNO) Competitors

$53.01 +0.00 (+0.01%)

Closing price 05/15/2026 07:41 PM Eastern

Extended Trading

$53.01 0.00 (0.00%)

As of 05/15/2026 07:41 PM Eastern

SLNO vs. FEMY, IMVT, GKOS, BLCO, and STVN

Should you buy Soleno Therapeutics stock or one of its competitors? MarketBeat compares Soleno Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Soleno Therapeutics include Femasys (FEMY), Immunovant (IMVT), Glaukos (GKOS), Bausch + Lomb (BLCO), and Stevanato Group (STVN). These companies are all part of the "medical" sector.

How does Soleno Therapeutics compare to Femasys?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Femasys	-521.97%	-258.08%	-73.72%

In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 3 articles in the media. Femasys' average media sentiment score of 0.63 beat Soleno Therapeutics' score of 0.33 indicating that Femasys is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 7.6% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Soleno Therapeutics has a beta of -2.22, suggesting that its stock price is 322% less volatile than the broader market. Comparatively, Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the broader market.

Soleno Therapeutics presently has a consensus target price of $76.67, indicating a potential upside of 44.62%. Femasys has a consensus target price of $5.33, indicating a potential upside of 1,377.38%. Given Femasys' stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95
Femasys	$2.29M	9.52	-$18.63M	-$0.27	N/A

Summary

Soleno Therapeutics beats Femasys on 10 of the 14 factors compared between the two stocks.

How does Soleno Therapeutics compare to Immunovant?

Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 3 articles in the media. Immunovant's average media sentiment score of 0.63 beat Soleno Therapeutics' score of 0.33 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Immunovant	N/A	-63.17%	-58.01%

Soleno Therapeutics has a beta of -2.22, suggesting that its stock price is 322% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Soleno Therapeutics presently has a consensus price target of $76.67, suggesting a potential upside of 44.62%. Immunovant has a consensus price target of $32.44, suggesting a potential upside of 23.43%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95
Immunovant	N/A	N/A	-$413.84M	-$2.69	N/A

Summary

Soleno Therapeutics beats Immunovant on 10 of the 14 factors compared between the two stocks.

How does Soleno Therapeutics compare to Glaukos?

Glaukos (NYSE:GKOS) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

In the previous week, Glaukos had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 5 mentions for Glaukos and 3 mentions for Soleno Therapeutics. Glaukos' average media sentiment score of 0.56 beat Soleno Therapeutics' score of 0.33 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soleno Therapeutics has a net margin of 33.70% compared to Glaukos' net margin of -34.34%. Soleno Therapeutics' return on equity of 22.85% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-34.34%	-6.92%	-5.25%
Soleno Therapeutics	33.70%	22.85%	18.25%

Soleno Therapeutics has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	16.44	-$187.69M	-$3.28	N/A
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95

Glaukos currently has a consensus target price of $144.42, suggesting a potential upside of 1.69%. Soleno Therapeutics has a consensus target price of $76.67, suggesting a potential upside of 44.62%. Given Soleno Therapeutics' higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

99.0% of Glaukos shares are held by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 6.4% of Soleno Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Glaukos has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, indicating that its stock price is 322% less volatile than the broader market.

Summary

Glaukos beats Soleno Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Soleno Therapeutics compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Bausch + Lomb had 3 more articles in the media than Soleno Therapeutics. MarketBeat recorded 6 mentions for Bausch + Lomb and 3 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 0.33 beat Bausch + Lomb's score of 0.11 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soleno Therapeutics has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.21B	1.09	-$360M	-$0.62	N/A
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95

Bausch + Lomb has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, suggesting that its share price is 322% less volatile than the broader market.

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bausch + Lomb currently has a consensus price target of $18.08, indicating a potential upside of 13.09%. Soleno Therapeutics has a consensus price target of $76.67, indicating a potential upside of 44.62%. Given Soleno Therapeutics' higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has a net margin of 33.70% compared to Bausch + Lomb's net margin of -4.21%. Soleno Therapeutics' return on equity of 22.85% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Soleno Therapeutics	33.70%	22.85%	18.25%

Summary

Soleno Therapeutics beats Bausch + Lomb on 11 of the 16 factors compared between the two stocks.

How does Soleno Therapeutics compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, profitability, valuation and dividends.

97.4% of Soleno Therapeutics shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Stevanato Group has higher revenue and earnings than Soleno Therapeutics. Soleno Therapeutics is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	4.02	€158.21M	€0.59	30.19
Soleno Therapeutics	$190.40M	14.51	$20.89M	$1.77	29.95

In the previous week, Soleno Therapeutics had 2 more articles in the media than Stevanato Group. MarketBeat recorded 3 mentions for Soleno Therapeutics and 1 mentions for Stevanato Group. Soleno Therapeutics' average media sentiment score of 0.33 beat Stevanato Group's score of 0.00 indicating that Soleno Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Stevanato Group has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, meaning that its share price is 322% less volatile than the broader market.

Soleno Therapeutics has a consensus price target of $76.67, suggesting a potential upside of 44.62%. Given Soleno Therapeutics' higher possible upside, analysts plainly believe Soleno Therapeutics is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has a net margin of 33.70% compared to Stevanato Group's net margin of 11.76%. Soleno Therapeutics' return on equity of 22.85% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
Soleno Therapeutics	33.70%	22.85%	18.25%

Summary

Soleno Therapeutics beats Stevanato Group on 10 of the 15 factors compared between the two stocks.

Get Soleno Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLNO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLNO vs. The Competition

Export

Metric	Soleno Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.76B	$2.97B	$6.24B	$12.21B
Dividend Yield	N/A	1.98%	2.81%	5.30%
P/E Ratio	29.95	17.29	20.67	25.15
Price / Sales	14.51	245.29	547.14	70.90
Price / Cash	124.10	56.35	27.48	37.27
Price / Book	6.33	3.93	9.70	6.65
Net Income	$20.89M	$74.99M	$3.56B	$335.32M
7 Day Performance	0.14%	-4.66%	-1.79%	-1.71%
1 Month Performance	0.44%	-7.63%	-2.50%	-1.07%
1 Year Performance	-29.33%	32.24%	31.39%	28.18%

Soleno Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLNO Soleno Therapeutics	3.7456 of 5 stars	$53.01 +0.0%	$76.67 +44.6%	-29.3%	$2.76B	$190.40M	29.95	30	High Trading Volume
FEMY Femasys	2.6438 of 5 stars	$0.40 -6.0%	$5.50 +1,260.7%	-66.4%	$25.96M	$2.29M	N/A	30	Gap Up
IMVT Immunovant	2.1124 of 5 stars	$29.06 +0.4%	$32.44 +11.6%	+90.1%	$5.89B	N/A	N/A	120
GKOS Glaukos	2.2597 of 5 stars	$135.17 +1.2%	$144.42 +6.8%	+50.4%	$7.84B	$507.44M	N/A	1,094
BLCO Bausch + Lomb	4.3471 of 5 stars	$16.10 -0.5%	$18.08 +12.3%	+36.7%	$5.77B	$5.21B	N/A	13,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLNO) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Soleno Therapeutics (SLNO) Competitors

SLNO vs. FEMY, IMVT, GKOS, BLCO, and STVN

How does Soleno Therapeutics compare to Femasys?

Summary

How does Soleno Therapeutics compare to Immunovant?

Summary

How does Soleno Therapeutics compare to Glaukos?

Summary

How does Soleno Therapeutics compare to Bausch + Lomb?

Summary

How does Soleno Therapeutics compare to Stevanato Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO vs. The Competition

Soleno Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Soleno Therapeutics (SLNO) Competitors

SLNO vs. FEMY, IMVT, GKOS, BLCO, and STVN

How does Soleno Therapeutics compare to Femasys?

Is SLNO or FEMY more profitable?

Does the media prefer SLNO or FEMY?

Do institutionals and insiders have more ownership in SLNO or FEMY?

Which has more risk & volatility, SLNO or FEMY?

Do analysts prefer SLNO or FEMY?

Which has preferable valuation and earnings, SLNO or FEMY?

Summary

How does Soleno Therapeutics compare to Immunovant?

Does the media refer more to SLNO or IMVT?

Is SLNO or IMVT more profitable?

Which has more risk & volatility, SLNO or IMVT?

Do analysts recommend SLNO or IMVT?

Do insiders & institutionals have more ownership in SLNO or IMVT?

Which has higher earnings & valuation, SLNO or IMVT?

Summary

How does Soleno Therapeutics compare to Glaukos?

Does the media favor GKOS or SLNO?

Is GKOS or SLNO more profitable?

Which has preferable earnings & valuation, GKOS or SLNO?

Do analysts recommend GKOS or SLNO?

Do institutionals and insiders hold more shares of GKOS or SLNO?

Which has more risk & volatility, GKOS or SLNO?

Summary

How does Soleno Therapeutics compare to Bausch + Lomb?

Does the media prefer BLCO or SLNO?

Which has stronger earnings and valuation, BLCO or SLNO?

Which has more risk & volatility, BLCO or SLNO?

Do institutionals & insiders believe in BLCO or SLNO?

Do analysts recommend BLCO or SLNO?

Is BLCO or SLNO more profitable?

Summary

How does Soleno Therapeutics compare to Stevanato Group?

Do insiders and institutionals hold more shares of STVN or SLNO?

Which has higher valuation and earnings, STVN or SLNO?

Does the media refer more to STVN or SLNO?

Which has more volatility & risk, STVN or SLNO?

Do analysts prefer STVN or SLNO?

Is STVN or SLNO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO vs. The Competition

Soleno Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools